CLINICAL TRIAL: ADENOVIRUS CD-154 IN SUBJECTS WITH CLL

临床试验：腺病毒 CD-154 在 CLL 受试者中的应用

• 批准号: 8166877
• 负责人: JANUARIO E CASTRO
• 金额: $ 1.16万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166877
• 关键词: Adenovirus 5-CD40-L Vector; Adenoviruses; Biological Monitoring; Chronic Lymphocytic Leukemia; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diffuse; Follicular Lymphoma; Funding; Grant; Injection of therapeutic agent; Institution; Large-Cell Lymphomas; Mantle Cell Lymphoma; Non-Hodgkin' s Lymphoma; Patients; Pharmacodynamics; Research; Research Personnel; Resources; Safety; Small-Cell Lymphoma; Source; United States National Institutes of Health; lymph nodes; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives Determine and monitor the biological responses in patients with Non-Hodgkin lymphoma (NHL) restricted to follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL) treated with repeat intranodal injections of Ad-ISF35. Secondary Objectives 1) Determine the safety of repeat administration of Adenovirus-CD154 (Ad-ISF35) injected directly into lymph nodes of patients with Non-Hodgkin lymphoma (NHL) including follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL). 2) Determine pharmacodynamic (PD) parameters in patients treated with repeat intranodal injections of Ad-ISF35.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 主要目标 确定和监测非霍奇金淋巴瘤 (NHL) 患者的生物学反应，仅限于滤泡性淋巴瘤、弥漫性大细胞淋巴瘤、套细胞淋巴瘤和小淋巴细胞淋巴瘤/慢性淋巴细胞白血病 (SLL/CLL)，经重复结内注射 Ad-ISF35 治疗。 次要目标 1) 确定将腺病毒-CD154（Ad-ISF35）直接注射到非霍奇金淋巴瘤（NHL）患者淋巴结中的安全性，包括滤泡性淋巴瘤、弥漫性大细胞淋巴瘤、套细胞淋巴瘤和小淋巴细胞淋巴瘤/慢性淋巴细胞白血病（SLL/CLL）。 2) 确定重复结内注射 Ad-ISF35 治疗的患者的药效学 (PD) 参数。